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Background. This study aimed to investigate prognostic factors for patients with myxoid/round-cell liposarcoma (MRCLS), in
particular the signiﬁcance of the round cell component, and to identify metastatic patterns as well as possibly suggest a suitable
strategy for followup. Methods. Clinical, morphologic, and follow-up data from 160 patients with MRCLS was reviewed and
statistically analysed. Results. Of 130 tumours with the round cell component evaluated, 61 had no round cell component, 27 had
<5% round cell component, and 42 had >5%. All patients underwent surgical excision, 15 requiring amputation. 107 patients
received adjuvant radiotherapy. Local recurrence occurred in 19 patients (12%), predominantly in patients with marginal or
intralesional margins and a round cell component. Overall disease speciﬁc survival was 75% at 5 years and 56% at 10years and was
relatedtotheproportionofroundcellcomponent.Of52patientswhodevelopedmetastases,38(73%)hadpurelyextrapulmonary
metastases. We could not identify any factors predicting the site of metastases developing. Conclusions. The occurrence of any
round cell component is the most important adverse prognostic factor for patients with MRCLS; patients with >5% round cell
component are at higher risk of local recurrence, metastasis and tumour-related death and should be considered for adjuvant
radiotherapy and possibly chemotherapy. The best method of monitoring extrapulmonary metastases remains to be established.
1.Introduction
Liposarcomas, which constitute a family of malignant mes-
enchymal neoplasms showing adipocytic diﬀerentiation, are
the most common soft tissue sarcoma in adults [1]. Four
main forms of liposarcoma are recognized: atypical lipoma-
tous tumour/well-diﬀerentiated liposarcoma, dediﬀerenti-
ated liposarcoma, myxoid/round-cell liposarcoma, and pleo-
morphic liposarcoma [2]. Myxoid/round-cell liposarcoma
(MRCLS) is the second most common subtype of liposar-
coma. Histologically MRCLS shows a continuous spectrum
of lesions which at one end of the spectrum exhibit a striking
resemblance to developing foetal fat with ample lipoblast
diﬀerentiation and at the other end of the spectrum show
poorly diﬀerentiated round cell features with at best incon-
spicuous lipoblast diﬀerentiation. The continuous morpho-
logic spectrum, the shared clinical characteristics, and the
common chromosome translocation t(12; 16), resulting in
the fusion of the TLS (FUS) and CHOP (DDT3) genes
seen in most of these tumours, clearly indicate that MRCLS
represents a distinct family among liposarcomas [3–6].
Thesubclassiﬁcationofliposarcomashasadramaticpro-
gnostic signiﬁcance; while tumours in the spectrum of atypi-
callipomatoustumours/well-diﬀerentiatedliposarcomaonly
carryariskoflocalrecurrenceandpossibledediﬀerentiation,
the pleomorphic liposarcomas are high-grade malignancies
with a very high risk of metastatic disease [2]. MRCLS
carries an intermediate risk with approximately one-third of
patients developing metastases and eventually dying of their
tumours [7–10]. Another feature distinguishing MRCLS
from the other types of liposarcoma and most other soft
tissuesarcomasisitstendencytometastasizetoothersofttis-
sue sites, including the trunk and extremities, the retroperi-
toneum, the chest wall, the pleura, and the pericardium [11–
13]. Factors found to inﬂuence the prognosis of MRCLS
includethepatient’sage,tumoursize,tumourgrade,tumour2 Sarcoma
depth, and the surgical margins achieved [14–16]. When
compared to other types of liposarcoma, MRCLS shows an
unusually high response rate to both adjuvant radiotherapy
and chemotherapy [17–19]. Morphologic factors reported to
be of prognostic signiﬁcance in MRCLS include tumour
necrosis, grading based on diﬀerentiation, necrosis and mi-
totic rate, proliferation index (MiB-1, Ki-67 immunostain),
and P53 overexpression [8–10, 14]. Of particular interest is
the fact that the rare, purely round cell liposarcoma has a
clearly worse prognosis than the purely myxoid liposarcoma
[15]. Also, smaller components of round cells have been
shown to inﬂuence the prognosis. Kilpatrick et al. have
suggested a three-tiered system (0–5%, 5–25%, >25%) while
Antonescu et al. have proposed a two-tiered system (< or
>5% round cell component) [8, 16]. Others have found that
any round cell component is associated with a worse out-
come [14].
The aim of this retrospective analysis was to attempt to
conﬁrm or refute the previously identiﬁed clinicopathologic
prognosticfactorsforpatientswithMRCLSandinparticular
to analyse the signiﬁcance of morphologic features based on
a large single centre series with long-term followup. We also
wished to investigate further the propensity for MRCLS to
metastasizeoutsidethelungsinordertoestablish,ifpossible,
a reasonable followup policy for patients with this tumour.
2.MaterialsandMethods
We retrospectively reviewed the records and histopathology
of all newly diagnosed patients with morphologically proven
MRCLS treated at our unit from January 1987 to December
2005 (thus, allowing a minimum two-year followup). Data
wascollectedfromaprospectivedatabasewhichhascollected
information on patients, tumours, treatment, and outcome
since 1986. Patients were excluded from the study if they
were referred for a second opinion and were not treated at
our centre or if they had metastases or local recurrence on
presentation. We included patients who had undergone a
previous biopsy or inadvertent excision. Out of a total of 190
patients with a diagnosis of MRCLS in the 18-year period
under investigation, twelve patients with metastases at the
time of diagnosis and eighteen patients referred with local
recurrence after previous treatment were excluded. All the 12
patients with metastases at presentation (who were excluded
from the study) died within three years. The remaining 160
patientswerefollowedupforaminimumoftwoyears(mean
7.2years, median 4.6years) as of December 2007.
The data collected from the database included a wide
range of variables including patient characteristics (age, sex),
tumour characteristics (site, size, duration of symptoms,
depth, stage, histopathological variables), management (bio-
psy type, operation type and margins achieved, use of adju-
vant therapy), and followup (development of local recur-
rence, distant metastasis, and survival). For patients who had
not been seen in the past year or who had been discharged,
followup was carried out using the NHS tracking system
linked to the cancer registry to identify if the patients
had died and their cause of death. The tumour locations
were classiﬁed as central if the tumour was located in
the trunk (proximal to hip and shoulder joint), upper
extremity if it was beyond the shoulder joint, and lower
extremity if it was beyond the hip joint. Tumour size was
deﬁned as the diameter of the primary tumour in maximum
dimensionasreportedatthetimeofinitialsurgicalresection.
Tumour depth was deﬁned in relation to the superﬁcial in-
vesting fascia. All retroperitoneal, abdominal, or pelvic loca-
tions were considered deep.
The diagnosis of MRCLS was based on histopathologic
examination of needle trucut biopsy, open incisional/ex-
cisional biopsy, or a previous inadequate excision of the
tumourinthemistakenbeliefofabenignlesionatanoutside
centre. In the event of inadvertent excision carried out in an
from an outside centre, the patient was referred to our unit
for further management. Our policy in these cases was to
restagethe patient andusuallyto carry out a wide re-excision
[20].
Histologically the MRCLS resection specimens were clas-
siﬁed as of purely myxoid type or of myxoid type with a
round cell component. Tumours within the purely myxoid
subgroup showed a wide morphologic spectrum in terms
of cellularity and lipogenic diﬀerentiation but were all char-
acterized by bland, uniform, fusiform, or round cells in a
myxoid background and a prominent delicate, plexiform
capillary network. Round cell components were either seen
as sharply demarcated nodules or as a gradual transition
from cellular areas of myxoid liposarcomas. Round cell
componentsweredeﬁnedashighlycellularareaswithbackto
back primitive round cells with increased nucleocytoplasmic
ratio and usually prominent nucleoli. Such areas lacked the
myxoid background, and the capillary network could usually
not be discerned (Figure 1). In purely myxoid liposarcomas,
the most cellular areas were selected, and in tumours with a
r o u n dc e l lc o m p o n e n tt h ea r e a sw e r er e c o r d e d .
According to the Trojani grading system, purely myxoid
liposarcomas are grade 2, while tumours with a prominent
round cell component are grade 3 [3, 21]. The round cell
component in myxoid liposarcoma was initially evaluated as
a continuous variable but was later divided into three cate-
gories on the basis of percentage of round cell component:
(1) 0% round cell, (2) <5% round cell, (3) >5% round cell.
Histologic material was only available for review in 130 of
the 160 patients (81%). Since all of these cases had been
externally reviewed in 1993, we included these cases in the
statistical analysis of clinical factors [22].
Following diagnosis and staging, the primary manage-
ment aimed to excise the tumour with wide margins wher-
ever possible [23]. When the tumour was adjacent to a criti-
cal structure (e.g., nerve, bone, blood vessel), a planned mar-
ginal margin was usually accepted [24]. Amputation was
reserved for large tumours which could only be surgically
removed safely by such a procedure. Postoperative radiother-
apy (usually 60Gy) was given to most patients with large
(>5cm), deep tumours with marginal margins of excision.
Chemotherapy was only given to patients with metastatic
disease. Patients were followed up 3 times monthly for two
years, 6 times monthly until 5 years, and then annually for
8 years. They had a routine chest radiograph at each clinicSarcoma 3
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Figure 1: Paucicellular myxoid liposarcoma with obvious lipoblastic diﬀerentiation (a), cellular variant of myxoid liposarcoma (b), and
typical round cell component (c). (Hematoxylin-eosin).
visit but had no other routine imaging unless the patient or
reviewing doctor was concerned.
2.1. Statistical Methods. Survival time was taken from the
date of diagnosis to the last date when the patient was docu-
mented to be alive or the date of death. Diﬀerences between
groups were analysed using the chi-squared test for discrete
variables or use of the two-sample t-test or Mann-Whitney
test for continuous variables. Survival analysis was done
using the Kaplan-Meier survivorship. The Cox proportional
hazardsregressionmodelwasusedtoassesstheeﬀect(hazard
ratio (HR)) on the primary outcome of age at diagnosis,
location of tumour (central versus peripheral), size, depth,
round cell percentage, type of surgery (limb salvage versus
amputation), and margins achieved (intralesional, marginal,
or wide).
For quantitative variables (continuous variables), we
reportthemedian,ﬁrst,andthirdquartilevalues.Categorical
variables are reported as counts. All analyses were performed
with Statview [25]. All tests were two sided, with a signif-
icance level of 0.05. When patients were grouped for more
detailed analysis, this has been clearly speciﬁed in the text
and the results.
3. Results
3.1. Clinicopathologic Factors. 160 patients were included in
the study; 99 were males (62%) and 61 females (38%). The
age range was 12 to 92 years (mean 48.6 years; median 47
years).The most common presenting complaint was devel-
opment of a painless soft tissue mass with duration of symp-
tomsrangingfrom1weekto15years(median6weeks,inter-
quartile range 50 weeks) prior to diagnosis. The anatomic
distribution of the primary tumours was as follows: 148
tumours occurred in the lower extremities (95 in the thigh,
23 in the lower leg, 14 in the buttock or hip, 8 in the foot
or ankle, and 8 in the knee or popliteal fossa). 7 tumours
occurred in the upper extremities (5 in the upper arm or
shoulder; 1 in the forearm, and 1 in the hand). 5 tumours
were central (3 in the lower back and 2 in the pelvis). The
tumoursizerangedfrom1to36cminthegreatestdimension
(mean: 11cm). Out of the 155 extremity tumours, only 31
were superﬁcial to the fascia. The superﬁcial tumours were
signiﬁcantly smaller than the deep tumours (P<0.0001)
with deep tumours averaging 13.3cm and superﬁcial 8.2cm.
There was no signiﬁcant diﬀerence in size between upper-
and lower-limb tumours.
All of the 130 histologically reviewed primary tumours
had predominantly or partly classical features of myxoid
liposarcoma. 61 (47%) were entirely of myxoid type while
69 (53%) had a round cell component present. 27 tumours
(21%) had a round cell component of 1–5% while 22
tumours (17%) contained a round cell component of 6–
25% and 20 tumours (15%) had a round cell component of
>25%. Of the latter group, 8 were almost entirely of round
cell type (>80% round cell component). There was no dif-
ference in tumour size, depth, or duration of symptoms
between tumours with and without a round cell component.
H o w e v e r ,a l lo ft h et u m o u r sw i t har o u n dc e l lc o m p o n e n t
occurred in the lower limb or trunk.
All patients underwent surgical excision of the primary
tumour with 141 undergoing excision alone, 3 having exci-
sionandsplitskingrafting,15undergoingamputation,and1
patient undergoing excision and endoprosthetic replacement
for a tumour that encircled and invaded the proximal femur.
Themarginswereevaluatedbothgrosslyandmicroscopically
in all dimensions. 55 patients had a wide excision, 86 a
marginal excision, and 19 an intralesional or contaminated
excision.
Postoperative radiotherapy was given to 107 patients
(67%). Radiotherapy was used increasingly over the period
of this study but was generally not used in patients who had
undergone an amputation or in those with small tumours
having undergone a wide excision. No patient received adju-
vant chemotherapy at the time of initial treatment. The
median followup for the 100 survivors was 6.7 years (range4 Sarcoma
Table 1: Risk factors for local recurrence at 5 years following tumour resection with hazards ratio estimates, 95% conﬁdence limits and P
values.
Factor 5 years risk of LR HR 95% CI P value
Overall 13%
Depth:
Superﬁcial 9% 1.46 0.42–5.00 0.55
Deep 14% 1
Size:
Up to 5cm 50% 2.285 0.63–8.27 0.208
>5cmto<10cm 7% 0.681 0.24–1.96 0.476
>10 cm 14% 1
Site:
Lower extremity 12% 0.269 0.06–1.18 0.081
Upper extremity 40% 1
Trunk 20% 0.605 0.60–6.76 0.683
Histology:
Pure myxoid 9% 1
0–5% round cell 4% 0.472 0.055–4.04 0.493
>5% round cell 26% 3.321 1.12–9.82 0.03
Margin:
Intralesional 34% 2.445 0.85–7.06 0.098
Marginal 6% 0.395 0.13–1.21 0.103
Wide 15% 1
Surgery:
Amputation 10% 0.625 0.083–4.69 0.648
Limb salvage 13% 1
Postoperative radiotherapy 11% 1
No radiotherapy 17% 1.13 0.429–2.977 0.80
7 months to 20 years) and was 3 years (range 1 month to
14.5 years) for the 60 who died. Only 46 of the deaths were
tumourrelated(mean3.4yearsfollowingdiagnosis)withthe
other 14 dying of a multitude of other causes (5 of other
cancers, 5 of cardiovascular disease, and 4 of other causes)
at a mean of 5.6 years following diagnosis (at an age ranging
between 60 and 98, mean 76 years).
3.2. Local Recurrence. 19 patients (12%) developed a local
recurrence at the primary site at a mean of 20 months. The
overall risk was 12.9% at 5 years and 14.3% at ten years.
The risk was directly related to the margins achieved with
the risk being 32% for patients with intralesional excisions,
6% for marginal excisions, and 14% for those with wide
excisions. The risk of local recurrence was also related to
the round cell component, being 26% in those with >5%
round cells. Because radiotherapy was used on an individual
case selection basis, it was diﬃcult to assess its beneﬁt. Local
recurrence occurred in 9 of the 87 patients with marginal
or intralesional excisions who received postoperative radio-
therapy (10%) compared with 2 of the 18 who did not have
radiotherapy (11%). The risk of local recurrence rose by a
factor of 3.3 for tumours with a round cell component >5%
whether they had radiotherapy or not (Table 1).
Of the 19 patients who developed local recurrence, 8
(42%) were found to have metastases synchronously and 5
(26%) developed metastases later (at a mean of 17 months),
whilst 6 patients (32%) have not developed metastases
(at a mean of 42 months since the development of local
recurrence). 12 of the 19 with local recurrence subsequently
died of metastases. 11 of the patients developed local recur-
rence within 18 months, and all but one of these patients
subsequentlydiedofmetastases(91%).Ofthe8patientswho
developedlocalrecurrenceafter18months,only2havesince
died of disease (25%) (P = 0.0033 Chi square).
3.3. Metastases. 52 patients (32.5%) developed metastases;
the estimated risk of metastases developing was 34% at 5
years and 40% at ten years. The risk factors for development
of metastases are shown in Table 2 and the time to develop-
ment of these metastases with regard to the round cell com-
ponent in Figure 2. In 7 patients the ﬁrst site of metastases
was in the lung alone, another 7 developed concomitant
ﬁrst metastases in the lung and another extrapulmonary
site, and 38 patients developed extrapulmonary metastases
alone. Among the extrapulmonary metastases, there was
a wide variety of sites, with 5 patients having subcuta-
neous metastases, 8 developing limb muscle metastases, andSarcoma 5
Table 2: Factors leading to development of metastatic disease and risk of developing this within 5 years, showing hazards ratio estimates,
95% conﬁdence limits and P values.




Deep 37% 1.443 0.68–3.07 0.341
Size:
Up to 5cm 22% 0.771 0.24–2.52 0.667
>5cmto<10cm 28% 0.69 0.38–1.27 0.232
>10cm 38% 1
Site:
Lower extremity 33% 0.889 0.22–3.66 0.871
Upper extremity 40% 1
Trunk 20% 0.780 0.07–8.68 0.84
Histology:
Pure myxoid 8% 1
0–5% round cell 35% 4.166 1.36–12.78 0.0126
>5% round cell 54% 8.899 3.35–23.64 <0.0001
Margin:
Intralesional 55% 1.347 0.61–2.96 0.459
Marginal 26% 0.722 0.39–1.31 0.286
Wide 37% 1
Surgery:
Amputation 73% 3.091 1.546–6.179 0.0014
Limb salvage 29% 1
Postoperative radiotherapy 28% 0.725 0.38–1.38 0.329
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Figure 2: Kaplan Meier survival curve showing patient survival
without development of metastatic disease split by round cell com-
ponent.
5 developing lymph node metastases. There were also 3 liver,
4 retroperitoneal, and 4 chest wall metastases with the
remaining 9 patients developing multiple extrapulmonary
sites of metastases. There was no clear correlation between
the site of ﬁrst metastases and the tumour size or round
cell component of the primary tumours. When appropri-
ate, metastases were surgically resected and some patients
received adjuvant chemotherapy or radiotherapy. It was not
infrequent for metastases to develop singly to start with and
then further metastases to appear with increasing frequency
[26]. Of the 52 patients who developed metastases, 38 had
died at the time of last followup of progressive disease,
with 2 dying of other causes. The median survival following
diagnosis of metastases was 8.5 months (range 0 to 107
months). Survival following the diagnosis of metastases was
not aﬀected either by the site of the ﬁrst metastases (lung or
other) or by the round cell component. The 12 patients still
alive following development of metastases have a followup
ranging from 0 to 150 months (median 9.5 months).
3.4. Survival. Overall survival was 69% at 5 years, 56% at ten
years, and 44% at 15 years. Disease-speciﬁc survival was 75%
at 5 years, 63% at ten years, and 59% at 15 years (Figure 3).
Factors aﬀecting survival are shown in Table 3. The most sig-
niﬁcantfactoraﬀectingprognosiswastheextentoftheround
cell component. Assessment of the signiﬁcance of varying6 Sarcoma
Table 3: Factors aﬀecting disease speciﬁc survival, showing hazards ratio estimates, 95% conﬁdence limits and P values.
Factor 5 years disease speciﬁc survival HR 95% CI P value
Overall 75%
Age under 50 81% 0.543 0.36–1.12 0.139
Age over 50 66% 1
Depth:
Superﬁcial 87% 1
Deep 71% 1.69 0.72–3.99 0.232
Size:
Up to 5cm 73% 0.647 0.15–2.71 0.552
>5cmto<10cm 78% 0.607 0.31–1.18 0.143
>10cm 72% 1
Site:
Lower extremity 76% 0.793 0.19–3.29 0.749
Upper extremity 60% 1
Trunk 50% 1.142 0.10–12.89 0.914
Histology:
Pure myxoid 91% 1
0–5% round cell 88% 2.785 0.80–9.69 0.107
>5% round cell 58% 6.897 2.53–18.82 0.0002
Margin:
Intralesional 70% 1.493 0.65–3.46 0.34
Marginal 78% 0.721 0.38–1.38 0.32
Wide 71% 1
Surgery:
Amputation 51% 3.062 1.47–6.37 0.0027
Limb salvage 77% 1
Postoperative radiotherapy 76% 1
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Figure 3: Disease-speciﬁc survival (all patients) with MRCLS.
proportions of round cell component revealed that tumours
with any round cell component (1–5% round cell compo-
nent) carried a worse prognosis than those with no round
cell component (Figure 4). This was, however, only appar-
ent with increasing followup as there was little diﬀerence at
5yearsbutadramaticdiﬀerenceat10years.Thesurvivalrate
attenyearswas91%forthosewithnoroundcellcomponent,
52% for those with up to 5% round cell component, and
only 31% for those with >5% round cell component. A
round cell component >5% carried the worst prognosis, but
increasing levels of round cell component did not make any
major diﬀerence to the prognosis, and the most obvious
cut-oﬀ level was at 5% (Figure 3). On multivariate analysis,
the round cell component remained a highly signiﬁcant
prognostic factor (Table 4). Interestingly both tumour size
>10cm and patient age >50 years were now signiﬁcant poor
prognostic factors as was amputation.
4. Discussion
This study reports on the clinical behavior and outcome in
termsoflocalcontrol,metastaticdisease,anddisease-speciﬁc
survival in 160 patients with primary myxoid/round-cell
liposarcoma, diagnosed and surgically treated at a single
centreoverthelast20years.Ourﬁndingsclearlyidentifythat
obtaining a good surgical margin is the most important
single factor for maintaining local control. The single, most
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Figure 4: Disease-speciﬁc survival with regards to the round cell
component of the tumours. It can be noted that extended follow-
up time patients with tumours with 1–5% round cell component
do less well than those with purely myxoid tumours while there
is no apparent diﬀerence between patients with 6–25% round cell
component and those with >25% round cell component.
Table 4: Multivariate analysis showing factors.
Factor HR 95% CI P value
Age under 50 0.415 0.190–0.908 0.0276
Size over 10cm 2.635 1.095–6.339 0.0305
Histology:
Pure myxoid 1
0–5% round cell 3.504 0.994–12.345 0.0510
>5% round cell 9.825 3.505–27.542 <0.0001
Surgery:
Amputation 3.271 1.161–9.221 0.0250
Limb salvage 1
was the occurrence of a round cell component, which also
increased the risk of local recurrence.
In this series the risk of local recurrence was 12.9% at
5 years, which compares very favorably with other reported
series. As expected there was a very strong correlation be-
tween risk of recurrence and margins achieved.
In a more recent Mayo Clinic series of 95 cases, 14%
developed local recurrence [8], and in a recent Dutch series
of 49 cases the local recurrence rate was 33% [15]. Fiore et
al. reported in a single centre study an overall risk of local
recurrence of 21.7% at 5 years [14]. This series, however,
included both primary and recurrent tumors; the recurrence
rate for the primary tumors was almost identical to ours,
with11.3% localrecurrenceinpatients withprimarymyxoid
liposarcoma patients and 13.7% for those with round cell
tumors.
The low local recurrence rate in their series of primary
tumors was believed to be explained partly by the fact that
almost half of the patients received postoperative radiother-
apy. Interestingly, we achieved similarly low recurrence rates
in our series in which 68% of all patients received adjuvant
radiotherapy.
Moreover, we found that the presence of a round cell
component increases the risk of local recurrence by more
than three times. Not surprisingly, the highest risk for local
recurrence was seen in patients with tumours having >5%
round cell component and involved or close margins. These
are, therefore, the patients that should principally be consid-
ered for adjuvant treatment, certainly with radiotherapy and
possibly chemotherapy. For patients with clear margins and
a purely myxoid liposarcoma without round cell component,
ourrecurrenceratewasverylow(4%,2/53patients).Forthis
group the value of radiotherapy is probably more question-
able.Thelowestrateoflocalrecurrenceinpatientswithmyx-
oid liposarcoma has been reported from the MD Anderson
Cancer Center; only 3% of 127 patients, all of whom were
treated with pre- or postoperative radiotherapy, developed
local recurrence [27]. The somewhat surprising eﬀectiveness
of radiotherapy in these, for the most part, low-grade, slow-
growing, and paucicellular tumours, is probably related to
a radiation-induced lipogenic diﬀerentiation and cell cycle
arrest [28]. It has also been suggested that the eﬀectiveness of
radiotherapy in myxoid liposarcoma is related to the radio-
sensitivity of the delicate vasculature, characteristic of these
tumours [29]. The occurrence of a local recurrence was in
this series associated with an increased risk of developing
metastases and tumour-related death. Thus, of the patients
who had a local recurrence, 68% developed synchronous or
subsequent metastases and 62% died of disease. Particularly
early recurrences in liposarcoma in general have been found
toindicateapoorprognosis[30].Ourﬁndingsshowthatthis
is also the case for the myxoid liposarcoma subtype. Whether
the local recurrence is just a marker of a tumour with an
aggressive behaviour or there is truly a causal association
between local recurrence and metastasis, in other word if the
local recurrence can be the source of metastases, remains, as
for other soft tissue sarcomas, an open question. In any case,
if such a causal association does exist, it is most likely weak
compared to other risk factors [31, 32].
The generally accepted prognostic factors for soft tissue
sarcomasaresize,grade,anddepthofthetumour,alongwith
patient age [33] .T h em e a nt u m o u rs i z ei nt h i ss e r i e sw a s
11cm, a similar ﬁgure to that in other series [8, 17, 28, 30].
Some of these studies have reported tumour size >10cm
to be associated with a poor prognosis, but, whilst we
were unable to conﬁrm this on univariate analysis, this was
signiﬁcant on multivariate analysis as was age over 50. The
depth of the tumour was not signiﬁcant in this series. This
is even more surprising as we found that the median size of
superﬁcial tumours was 8cm compared to a mean of 13cm
for deep tumours. There was no signiﬁcant diﬀerence in size
of tumours split by round cell component.
The risk factors for development of metastases and in-
deed for overall survival are not surprisingly quite similar
but are subtly diﬀerent from those found in the generality
of soft tissue sarcomas. Round cell component (and thus
grade) is the only signiﬁcant tumour factor whilst the need
to perform an amputation is the only treatment factor, and
this is likely to be a surrogate for a mixture of high-grade,
largein vasivetumourswhichmaybeexpectedtocarryapoor
prognosis. The overall disease-speciﬁc survival at 5 years of8 Sarcoma
91% for patients with pure myxoid liposarcomas and of 88%
for those with <5% round cell component again compares
favourablywiththosereportedbyothers.Fioreetal.reported
a 93% disease-speciﬁc survival for patients with myxoid
liposarcomawhichincludedallpatientswithupto5%round
cell component [14]. However, Fiore’s results for patients
with >5% round cell component of 87% ﬁve-year survival
are dramatically better that those in our experience, where
patients had only a 58% survival at 5 years. The reason for
this is not clear as Fiore et al. reported a 21.7% risk of
metastases at 5 years for this group compared to our 54%
risk. The diﬀerence in metastatic risk could be explained by
the use of adjuvant chemotherapy as this was used in 39
of 177 patients in Fiore’s series compared to none in ours.
Unfortunately it is not clear which patients received this,
but presumably those at greatest perceived risk (round cell
tumours) were selected (and this has since been conﬁrmed
(personal communication). Dalal et al. have, however,
followedaverysimilartreatmentprotocoltousandreported
a 92% ﬁve years disease-speciﬁc survival for patients with
less than 5% round cell component compared to a 74% ﬁve
yearsdisease-speciﬁcsurvivalforpatientswithmorethan5%
round cell component [34].
We have also conﬁrmed other opinions about the cutoﬀ
of 5% round cells as being a watershed between inter-
mediate- and high-risk tumours. We have, however, shown
thatanincreasing%ofroundcellsdoes notconferextrarisk,
and we have also shown that even patients with <5% round
cells are at greater risk of both metastases and death than
those with pure myxoid liposarcomas. Indeed, pure myxoid
liposarcoma with no round cell component has a very
good prognosis in our series with no tumour-related death
reported after the ﬁrst 18 months.
The role of adjuvant chemotherapy for patients with soft
tissue sarcomas has been extensively investigated [35], and
recent work has highlighted the potential sensitivity of myx-
oid liposarcomas to chemotherapy [18, 19, 27, 36]. Given
the high rate of metastatic disease developing in patients
with >5% round cell component, we consider this group of
patients to be at particular risk and suitable for future trials
of drug therapy. If patients develop round cell features at
the time of recurrence, then this also indicates a change to a
higher grade and the possible need for more aggressive treat-
ment [37].
Like others, we have found a high risk of metastases de-
veloping outside the lungs. In our series only 19% of ﬁrst
metastases were in the lung, and in half of these patients
other sites were identiﬁed on staging. 81% of ﬁrst metastases
were, thus, extrapulmonary but in a wide range of sites.
Therewas noobvious predictive factorwe couldidentify that
predicted whether a patient would develop pulmonary or
extrapulmonary metastases. We have only analysed the loca-
tionoftheﬁrstmetastasesbutnotedthesometimeprolonged
course of patients who develop extrapulmonary metastases
at a multitude of sites [26]. Estourgie found extrapulmonary
metastases in 12 of 22 patients with metastatic disease (55%)
and recommended that patients should be followed with
regular abdominal/pelvic CT scans [13]. If this had been
carried out in our patients, it would have detected the 14
patients with pulmonary metastases (all of whom had their
metastases identiﬁed by routine surveillance chest radio-
graph)butonly13oftheother38(34%)metastases,possibly
before they became symptomatic.
Cheng et al. found that patients with extremity liposar-
coma when metastasized had a 59% incidence of isolated
extrapulmonary metastasis [11], whilst Guadagnolo et al.
reported that 78% of all their metastases were extrapul-
monary and 48% were retroperitoneal [27]. Others have also
noted the high incidence of purely extrapulmonary metas-
tases, Fiore et al. reporting a rate of 41% [14], Ten Heuvel
et al. a rate of 77% [15], and Antonescu et al. a rate of 67%
[16].Alloftheseseriesnotedthatcommonsitesofmetastasis
were the retroperitoneum, abdominal or chest wall, and
abdominal cavity whilst Schwab et al. noted the presence of
skeletal metastases [38].
The question of how to follow up these patients has not
yet been answered. There are several reports of the failure of
bothPETscansandbonescanstodetectmyxoidliposarcoma
metastases [39, 40]. Other options of whole body CT or MRI
remain as possible screening tools, but there is lack of proof
for both clinical and cost eﬀectiveness. If we were to add
some form of whole-body imaging (e.g., whole-body MRI)
to our current protocol of clinical followup and chest radio-
graph, this may have detected 38 patients with metastases
at extrapulmonary sites before they became symptomatic.
Assuming that these metastases would have been detected on
average three months earlier by routine imaging than they
would have been by just clinical followup would have meant
that a total of 1578 scans would have been done to detect 30
extrapulmonary metastases in the ﬁrst ﬁve years following
diagnosis, that is, 52 scans for each metastasis detected. If the
scans were only done with half that frequency, then some of
the metastases may have become apparent in between scans,
but, assuming this was not the case, it would still mean 26
scansforeachmetastasisdetected.Ifonlypatientswithahigh
round cell (>5%) component were investigated; however,
the ﬁgures are more reasonable, with 17 extrapulmonary
metastases being potentially identiﬁed after 370 scans in
the ﬁrst ﬁve years, that is, 22 scans for each metastasis de-
tected. Whether earlier detection of these metastases would
inﬂuence outcome, however, remains unclear and is a topic
worthy of further investigation.
In conclusion we have conﬁrmed that the round cell
component is the most signiﬁcant predictor of behaviour of
the tumour for myxoid liposarcoma. Pure myxoid liposar-
coma is a relatively low-grade tumour which should be
treatedsurgicallywithattemptstoobtainclearmarginsofex-
cision. Patients with 0–5% round cell component repre-
sent an intermediate-grade tumour with a higher risk of
metastatic disease, whilst patients with >5% round cell com-
ponentmustbeconsideredtohaveahigh-gradetumourwith
a signiﬁcantly increased risk of both local recurrence and
metastases and should be treated with surgical excision with
clearmargins,radiotherapy,andpossiblychemotherapy.The
use of new agents may well be indicated for this patient
group. Awareness of the high incidence of extrapulmonary
metastases should lead to investigation of a suitable clinical
and cost-eﬀective method of screening for these, and thisSarcoma 9
may be particularly important if eﬀective new treatments for
metastatic disease become available.
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